Mortality at five years following valve-in-valve TAVR is comparable with that seen in native TAVR intermediate-risk patients, based on five-year follow-up from the PARTNER 2 trial looking at clinical outcomes, valve function and durability function presented Oct. 17 during TCT 2020.

John G. Webb, MD, FACC, et al., analyzed data from 365 patients in whom valve implant was completed. They noted that in survivors, early improvement in functional status and quality of life were maintained for five years. Additionally, rates of heart valve disease and bioprosthetic valve fracture were consistent with those reported for native SAPIEN XT valves in patient with intermediate risk.

Study investigators noted that these new findings add to the growing body of evidence regarding valve-in-valve TAVR, which has been associated with acceptable mortality, improved valve hemodynamics, and excellent quality of life outcomes at three years. However, limited data have been available to date on longer-term clinical outcomes, valve function and durability.

Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Aortic Surgery

Keywords: TCT20, Transcatheter Cardiovascular Therapeutics, Percutaneous Coronary Intervention, Aortic Valve, Heart Valve Prosthesis Implantation

< Back to Listings